Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324529 · ClinicalTrials.gov registry record · NA
Autonomic Modulation in Takotsubo Syndrome
A NA study of Takotsubo Syndrome, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03324529: Active NA study of Takotsubo Syndrome, sponsored by NYU Langone Health.
NCT03324529 is a NA study of Takotsubo Syndrome that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03324529, a NA study of Takotsubo Syndrome, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in laboratory testing to measure autonomic function. They will then undergo a 15-week program of device-guided breathing with remote measures of autonomic function obtained at home. Analysis will determine the reproducibility of home autonomic measures and the provide preliminary data to determine the efficacy of device-guided breathing on autonomic measures and quality of life in patients with takotsubo.
Primary Outcome
Remote heart rate monitoring with an adhesive chest telemetry patch and biosensor wrist watch
Conditions Studied
Interventions
- DEVICE Tako Breath
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2027-06 |
| Phase | NA |
What the registry record for NCT03324529 still lists
NCT03324529 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Takotsubo Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Tako Breath is the first listed.
NCT03324529 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03324529 about?
NCT03324529 is a clinical study titled "Autonomic Modulation in Takotsubo Syndrome". This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in laboratory testing to measure autonomic function. They will then undergo a 15-week program of device-gui...
What is the current status of trial NCT03324529?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2021-10-01. Estimated completion is 2027-06.
What conditions does trial NCT03324529 study?
This clinical trial studies the following conditions: Takotsubo Syndrome.
What interventions are being tested in trial NCT03324529?
The interventions under investigation include: Tako Breath (DEVICE).
Who is sponsoring clinical trial NCT03324529?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03324529 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03324529's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI